A therosclerosis is a lipid-driven, chronic inflammatory disorder that is characterized by the formation of leukocyte-rich plaques in large-and medium-sized arteries. Plaque macrophages form lipid-laden foam cells and eventually fail to clear the overwhelming number of apoptotic cells (failure of efferocytosis), forming a necrotic core. Other immune cells like T-and B-cell subsets contribute to atheroprogression by controlling the inflammatory milieu. The subject of the present work 1 concerns the role of natural killer (NK) cells in atherosclerosis progression.
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NK cells are found at an average of 1 to 2 cells per lesion section. 1 NK cells are potent immune cells protecting the host from viral infections and tumor formation. If a host cell lacks surface MHC-I (major histocompatibility complex I), being in a state of missing self, NK cells will kill this cell. NK cells also display immune-regulatory features and are capable of influencing antigen-specific T-cell responses. In the course of cardiovascular disease, the number of NK cells decreases in patients with stable angina or non-ST-segment-elevation myocardial infarction without affecting their cytokine expression profile.
2 Until now, 1 the role of NK cells in atherosclerosis had remained unclear and controversial.
In this issue of Circulation Research, Nour-Eldine et al 1 show that NK cells are not involved in atherosclerosis. A first study investigating NK cell activity in atherosclerosis assessed beige mice. Beige mice carry a mutation of the Lyst gene impairing NK cell activity. Beige mice fed a high-fat diet (HFD) with cholate did not display altered atherosclerotic lesion formation, whereas low-density lipoprotein receptor deficient (Ldlr −/− ) mice crossbred to beige mice harbored smaller lesions. This was interpreted to mean that NK cells may be proatherogenic. 3 However, beige mice have additional defects (Table) such as lysosomal storage impairments, which might affect other immune cells and thus atherosclerosis. 4 Further studies delineating NK cell activity involved transgenic mice expressing Ly49A under control of the granzyme A promoter. Ly49A is an MHC-I-binding receptor that inhibits NK cell function and survival. These mice have fewer NK cells. 5 The transplantation of bone marrow from these transgenic mice into Ldlr −/− mice reduced atherosclerosis, suggesting that NK cells may be proatherogenic. 6 However, granzyme A is also expressed by NKT (natural killer T cell) cells and CD8 T cells, which have been both identified as proatherogenic. [7] [8] [9] Thus, this model is not suitable to isolate the role of NK cell function.
A third set of studies applied rabbit anti-asialo-GM1 serum. Injection of this serum into apolipoprotein-deficient (Apoe −/− ) mice depleted NK cells and significantly reduced atherosclerosis formation, again ascribing NK cells a proatherogenic role. 10 However, the glycolipid asialo-GM1 is not exclusively expressed by NK cells but also by myeloid cells, T cells, and even epithelial cells. This suggests that anti-asialo-GM1 may have extraneous effects that confound the interpretation. Adoptive transfer of NK cells into lymphopenic and NK celldeficient Apoe −/− Rag2 −/− Il2rg −/− mice suggested that NK cells contribute to necrotic core formation and atheroprogression. 10 Nour-Eldine et al 1 looked at NK cell functionality in atherosclerosis using precise and specific genetic approaches. In the first model, Cre recombinase was controlled by the internal Ncr1 promoter (Ncr iCre ). The Ncr1 gene encodes the NK cell-specific inhibitory receptor NKp46 (natural cytotoxicity triggering receptor 1). These mice were crossed with transgenic mice expressing a flox-STOP-flox-controlled diphtheria toxin a (DTA) fragment in the Rosa26 locus (R26
lsl-DTA
). Cre-driven excision of the stop codon induced NK cell death by DTA expression. It should be noted though that a minor fraction of innate lymphoid cells in the liver and in the small intestine also express this marker and will be affected by the described deletion strategy. Nour-Eldine et al 1 mice. Again, Ldlr −/− mice receiving either bone marrow and a control antibody displayed similar levels of atherosclerosis, but injection of anti-asialo-GM1 serum into both types of mice significantly reduced atherosclerosis. Thus, anti-asialo-GM1 had significant effects on cells other than NK cells.
A third model carried the Noe mutation. 11 This point mutation generated by random mutagenesis prohibits NKp46 expression on the cell surface, thus rendering NK cells hyperresponsive, which leads to elevated production of the proinflammatory cytokine interferon-γ and a higher potential of degranulation. NourEldine et al 1 A strength of the present study is that 3 time points were studied (feeding HFD for 8, 12, or 15 weeks). A limitation is that type 1 and type 3 innate lymphoid cells (ILC) in the small intestine and in the liver also express NKp46 and thus were likely depleted or hyperactivated, respectively, in the mouse models used. Whereas CD25 + type 2 ILCs curb the development in atherosclerosis, 12 the role of ILC1 and ILC3 is unknown. The authors of the present study confirm that anti-asialo-GM1 treatment protects from atherosclerosis, but this is true even in mice lacking NK cells. Thus, previous results using anti-asialo-GM1 treatment must be reinterpreted. Another limitation is that bone marrow transplantations into Ldlr −/− mice can yield different results than mice in which the transgenes were crossed into the Ldlr −/− background. 13, 14 In conclusion, Nour-Eldine et al 1 find no effect of NK cell depletion or hyperactivation on atherosclerosis in the Ldlr −/− mouse model under HFD conditions. This resolves a longstanding controversy in the field.
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